|
1
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Soerjomataram I, Lortet-Tieulent J, Parkin
DM, Ferlay J, Mathers C, Forman D and Bray F: Global burden of
cancer in 2008: A systematic analysis of disability-adjusted
life-years in 12 world regions. Lancet. 380:1840–1850. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen D, Li SG, Chen JY and Xiao M: miR-183
maintains canonical Wnt signaling activity and regulates growth and
apoptosis in bladder cancer via targeting AXIN2. Eur Rev Med
Pharmacol Sci. 22:4828–4836. 2018.PubMed/NCBI
|
|
4
|
Stone L: Bladder cancer: Mastering the
immune microenvironment. Nat Rev Urol. 14:6392017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sargos P, Baumann BC, Eapen L,
Christodouleas J, Bahl A, Murthy V, Efstathiou J, Fonteyne V,
Ballas L, Zaghloul M, et al: Risk factors for loco-regional
recurrence after radical cystectomy of muscle-invasive bladder
cancer: A systematic-review and framework for adjuvant
radiotherapy. Cancer Treat Rev. 70:88–97. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grossman HB: Bladder cancer: Neoadjuvant
is new again. Lancet Oncol. 12:830–831. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morales-Barrera R, Suárez C, de Castro AM,
Racca F, Valverde C, Maldonado X, Bastaros JM, Morote J and Carles
J: Targeting fibroblast growth factor receptors and immune
checkpoint inhibitors for the treatment of advanced bladder cancer:
New direction and New Hope. Cancer Treat Rev. 50:208–216. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Abraham JM, Cheng Y, Wang Z, Wang
Z, Zhang G, Ashktorab H, Smoot DT, Cole RN, Boronina TN, et al:
Synthetic circular RNA functions as a miR-21 sponge to suppress
gastric carcinoma cell proliferation. Mol Ther Nucleic Acids.
13:312–321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hansen TB, Kjems J and Damgaard CK:
Circular RNA and miR-7 in cancer. Cancer Res. 73:5609–5612. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu J, Liu T, Wang X and He A: Circles
reshaping the RNA world: From waste to treasure. Mol Cancer.
16:582017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lasda E and Parker R: Circular RNAs:
Diversity of form and function. RNA. 20:1829–1842. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Feng J, Sun M, Yang G, Yuan H, Wang
Y, Bu Y, Zhao M, Zhang S and Zhang X: Long non-coding RNA HULC
activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in
HBV-related hepatocellular carcinoma. Cancer Lett. 454:158–170.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Chen M, Jiang N, Shi K and Qian
R: A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the
proliferation of lung adenocarcinoma. Cancer Biol Ther.
20:1127–1135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He J, Chen J, Ma B, Jiang L and Zhao G:
CircLMTK2 acts as a novel tumor suppressor in gastric cancer.
Biosci Rep. 39:392019. View Article : Google Scholar
|
|
15
|
Zhong Z, Lv M and Chen J: Screening
differential circular RNA expression profiles reveals the
regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in
bladder carcinoma. Sci Rep. 6:309192016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Glažar P, Papavasileiou P and Rajewsky N:
circBase: A database for circular RNAs. RNA. 20:1666–1670. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sebti SM and Adjei AA: Farnesyltransferase
inhibitors. Semin Oncol. 31 (Suppl 1):28–39. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42D:D92–D97. 2014. View Article : Google Scholar
|
|
19
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
eLife. 4:42015. View Article : Google Scholar
|
|
20
|
Matsushita R, Seki N, Chiyomaru T,
Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S,
Itesako T, et al: Tumour-suppressive microRNA-144-5p directly
targets CCNE1/2 as potential prognostic markers in bladder cancer.
Br J Cancer. 113:282–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Go H, Kim PJ, Jeon YK, Cho YM, Kim K, Park
BH and Ku JY: Sphingosine-1-phosphate receptor 1 (S1PR1) expression
in non-muscle invasive urothelial carcinoma: Association with poor
clinical outcome and potential therapeutic target. Eur J Cancer.
51:1937–1945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng J, Chen K, Dong X, Xu X, Jin Y, Zhang
X, Chen W, Han Y, Shao L, Gao Y, et al: Genome-wide identification
of cancer-specific alternative splicing in circRNA. Mol Cancer.
18:352019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su H, Tao T, Yang Z, Kang X, Zhang X, Kang
D, Wu S and Li C: Circular RNA cTFRC acts as the sponge of
microRNA-107 to promote bladder carcinoma progression. Mol Cancer.
18:272019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gu C, Zhou N, Wang Z, Li G, Kou Y, Yu S,
Feng Y, Chen L, Yang J and Tian F: circGprc5a promoted bladder
oncogenesis and metastasis through Gprc5a-targeting Peptide. Mol
Ther Nucleic Acids. 13:633–641. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen X, Chen RX, Wei WS, Li YH, Feng ZH,
Tan L, Chen JW, Yuan GJ, Chen SL, Guo SJ, et al: PRMT5 circular RNA
promotes metastasis of urothelial carcinoma of the bladder through
sponging miR-30c to induce epithelial-mesenchymal transition. Clin
Cancer Res. 24:6319–6330. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dangle PP, Zaharieva B, Jia H and Pohar
KS: Ras-MAPK pathway as a therapeutic target in cancer - emphasis
on bladder cancer. Recent Patents Anticancer Drug Discov.
4:125–136. 2009. View Article : Google Scholar
|
|
27
|
Chin K, DeVries S, Fridlyand J, Spellman
PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et
al: Genomic and transcriptional aberrations linked to breast cancer
pathophysiologies. Cancer Cell. 10:529–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qi X, Lin Y, Chen J and Shen B: Decoding
competing endogenous RNA networks for cancer biomarker discovery.
Brief Bioinform. Jan 30–2019.(Epub ahead of print).
doi.org/10.1093/bib/bbz006. View Article : Google Scholar
|
|
29
|
Zhao J, Liu J, Lee JF, Zhang W, Kandouz M,
VanHecke GC, Chen S, Ahn YH, Lonardo F and Lee MJ: TGF-β/SMAD3
pathway stimulates sphingosine-1 phosphate receptor 3 expression:
Implication of sphingosine-1 phosphate receptor 3 in lung
adenocarcinoma progression. J Biol Chem. 291:27343–27353. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hirata N, Yamada S, Shoda T, Kurihara M,
Sekino Y and Kanda Y: Sphingosine-1-phosphate promotes expansion of
cancer stem cells via S1PR3 by a ligand-independent Notch
activation. Nat Commun. 5:48062014. View Article : Google Scholar : PubMed/NCBI
|
